Đang chuẩn bị liên kết để tải về tài liệu:
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitornaïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Liên Hoa 141 11 pdf

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG Tải xuống

Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR mutation-positive nonsmall cell lung cancer (NSCLC). In this Korean expanded access program, we evaluated its ‘real-world’ safety and efficacy. |

TÀI LIỆU LIÊN QUAN

TRIBE-2: A phase III, randomized, openlabel, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: An openlabel, phase I trial with an extensive biomarker program

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled openlabel phase II trial

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.

Đang chuẩn bị liên kết để tải về tài liệu: An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitornaïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR mutation-positive nonsmall cell lung cancer (NSCLC). In this Korean expanded access program, we evaluated its ‘real-world’ safety and efficacy. |

TRIBE-2: A phase III, randomized, openlabel, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: An openlabel, phase I trial with an extensive biomarker program

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled openlabel phase II trial

Đang chuẩn bị liên kết để tải về tài liệu:
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitornaïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations